Compare NGVC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVC | TBPH |
|---|---|---|
| Founded | 1955 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.8M | 908.9M |
| IPO Year | 2012 | 2013 |
| Metric | NGVC | TBPH |
|---|---|---|
| Price | $31.04 | $16.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $36.00 | $18.40 |
| AVG Volume (30 Days) | 106.3K | ★ 911.9K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | 36.05 | ★ 279.13 |
| EPS | ★ 1.07 | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $7.08 | $8.46 |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $29.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.47 | $10.82 |
| 52 Week High | $45.98 | $21.03 |
| Indicator | NGVC | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 49.67 |
| Support Level | $30.36 | $16.17 |
| Resistance Level | $31.94 | $17.21 |
| Average True Range (ATR) | 1.15 | 0.11 |
| MACD | -0.27 | -0.04 |
| Stochastic Oscillator | 13.51 | 8.33 |
Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories: natural and organic food, dietary supplements, natural body care, household, pet care products, books, and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business is conducted. The company generates the majority of its revenue from grocery products and dietary supplements, and the rest from other products.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.